The Recovery of Cognitive and Affective Deficiencies Linked with Chronic Osteoarthritis Pain and Implicated Pathways by Slow-Releasing Hydrogen Sulfide Treatment.

Gerard Batallé, Xue Bai, Enric Pouso-Vázquez, Gerad Roch, Laura Rodríguez, Olga Pol
Author Information
  1. Gerard Batallé: Grup de Neurofarmacologia Molecular, Institut d'Investigació Biomèdica Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  2. Xue Bai: Grup de Neurofarmacologia Molecular, Institut d'Investigació Biomèdica Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain. ORCID
  3. Enric Pouso-Vázquez: Grup de Neurofarmacologia Molecular, Institut d'Investigació Biomèdica Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  4. Gerad Roch: Grup de Neurofarmacologia Molecular, Institut d'Investigació Biomèdica Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  5. Laura Rodríguez: Grup de Neurofarmacologia Molecular, Institut d'Investigació Biomèdica Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  6. Olga Pol: Grup de Neurofarmacologia Molecular, Institut d'Investigació Biomèdica Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain. ORCID

Abstract

Chronic osteoarthritis pain is accompanied by several comorbidities whose treatment has not been completely resolved. The anti-inflammatory, analgesic, and antidepressant effects of slow-releasing hydrogen sulfide (HS) donors during osteoarthritic pain have been shown, but their actions in the accompanying memory impairment and anxious-like behaviors have not yet been demonstrated. Using female mice with chronic osteoarthritic pain, the effects of natural, diallyl disulfide (DADS) or synthetic, morpholin-4-ium 4-methoxyphenyl(morpholino) phosphinodithioate dichloromethane complex (GYY4137) slow-releasing HS donors, on associated cognitive and grip strength deficits and anxiodepressive-like behaviors, were assessed. Their effects on specific brain areas implicated in the modulation of pain and emotional responses were also determined. Results demonstrated an improvement in memory and grip strength deficits, as well as in the anxious-like behaviors associated with chronic pain in GYY4137 and/or DADS treated mice. The painkiller and antidepressant properties of both treatments were also established. Treatment with DADS and/or GYY4137 inhibited: oxidative stress in the amygdala; phosphoinositide 3-kinase overexpression in the amygdala, periaqueductal gray matter, and anterior cingulate cortex; protein kinase B activation in the amygdala and infralimbic cortex; up-regulation of inducible nitric oxide synthase in the amygdala, periaqueductal gray matter and infralimbic cortex and apoptotic responses in the amygdala. These results might explain the recovery of memory and grip strength and the inhibition of allodynia and associated anxiodepressive-like behaviors by these treatments. In conclusion, this study revealed new properties of slow-releasing HS donors in cognitive impairment and affective disorders linked with chronic osteoarthritis pain and their effects on the central nervous system.

Keywords

References

  1. Expert Rev Neurother. 2020 Jan;20(1):109-121 [PMID: 31530193]
  2. J Pain Res. 2020 Feb 11;13:345-354 [PMID: 32104056]
  3. Front Pharmacol. 2018 Nov 20;9:1332 [PMID: 30542282]
  4. Antioxid Redox Signal. 2018 Jun 1;28(16):1533-1540 [PMID: 28388861]
  5. Biomed Pharmacother. 2020 Jul;127:110210 [PMID: 32407991]
  6. Antioxidants (Basel). 2019 Dec 29;9(1): [PMID: 31905764]
  7. Cartilage. 2020 Jan;11(1):38-46 [PMID: 29855190]
  8. Neural Plast. 2017;2017:9724371 [PMID: 28706741]
  9. Exp Ther Med. 2019 Jul;18(1):678-684 [PMID: 31281447]
  10. Front Pharmacol. 2019 May 03;10:468 [PMID: 31130863]
  11. Eur J Pharmacol. 2021 Apr 5;896:173883 [PMID: 33513334]
  12. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589 [PMID: 31278997]
  13. Inflamm Allergy Drug Targets. 2011 Apr;10(2):109-17 [PMID: 21275894]
  14. J Pain Res. 2018 Nov 19;11:2905-2913 [PMID: 30510445]
  15. Osteoarthritis Cartilage. 2020 Apr;28(4):400-409 [PMID: 32081707]
  16. J Mol Neurosci. 2018 May;65(1):93-101 [PMID: 29728964]
  17. Neuroscience. 2015 Sep 10;303:577-85 [PMID: 26192092]
  18. Int J Mol Sci. 2020 Oct 08;21(19): [PMID: 33050005]
  19. Neuropharmacology. 2017 Oct;125:231-242 [PMID: 28760650]
  20. Int J Mol Sci. 2020 May 13;21(10): [PMID: 32414089]
  21. Cell Physiol Biochem. 2018;48(5):1815-1828 [PMID: 30092586]
  22. Brain Res. 2011 Aug 2;1404:63-71 [PMID: 21704983]
  23. Int J Rheum Dis. 2019 Mar;22(3):399-410 [PMID: 30585422]
  24. Osteoarthritis Cartilage. 2008;16 Suppl 2:S15-20 [PMID: 18794013]
  25. Nat Protoc. 2007;2(2):322-8 [PMID: 17406592]
  26. J Neurosci. 2013 Apr 24;33(17):7603-14 [PMID: 23616565]
  27. Expert Opin Ther Targets. 2018 Apr;22(4):299-318 [PMID: 29504411]
  28. Chronic Illn. 2021 Mar;17(1):41-52 [PMID: 30587007]
  29. J Neurosci Methods. 1994 Jul;53(1):55-63 [PMID: 7990513]
  30. Front Cell Dev Biol. 2021 Apr 07;9:634810 [PMID: 33898422]
  31. Open Access Rheumatol. 2016 Oct 31;8:103-113 [PMID: 27843376]
  32. Neuropsychol Rev. 2000 Sep;10(3):131-49 [PMID: 10983898]
  33. J Affect Disord. 2018 Aug 1;235:96-104 [PMID: 29655081]
  34. Neurosci Lett. 2017 Aug 10;655:7-13 [PMID: 28648456]
  35. J Cell Mol Med. 2013 Mar;17(3):365-76 [PMID: 23356870]
  36. Nature. 1977 Apr 21;266(5604):730-2 [PMID: 559941]
  37. Behav Pharmacol. 2013 Oct;24(7):590-7 [PMID: 23974423]
  38. Arthritis Rheum. 2009 Feb;60(2):492-500 [PMID: 19180501]
  39. Med Pharm Rep. 2020 Jan;93(1):12-22 [PMID: 32133442]
  40. J Cell Mol Med. 2012 Apr;16(4):896-910 [PMID: 21679296]
  41. Brain. 2008 Dec;131(Pt 12):3222-31 [PMID: 18819988]
  42. Hum Brain Mapp. 2021 Mar;42(4):1206-1222 [PMID: 33210801]
  43. Psychopharmacology (Berl). 1985;85(3):367-70 [PMID: 3923523]
  44. Antioxidants (Basel). 2021 Jul 03;10(7): [PMID: 34356307]
  45. PLoS One. 2018 Feb 21;13(2):e0192556 [PMID: 29466396]
  46. Arthritis Rheum. 2000 Jun;43(6):1290-9 [PMID: 10857787]
  47. Neurosci Biobehav Rev. 2008 Sep;32(7):1326-35 [PMID: 18573531]
  48. Med Res Rev. 2021 Jan;41(1):136-155 [PMID: 32820550]
  49. Can J Physiol Pharmacol. 2019 Jan;97(1):47-54 [PMID: 30521368]
  50. Contemp Clin Trials Commun. 2021 Jan 28;21:100720 [PMID: 33553798]
  51. Biochem Pharmacol. 2019 Jul;165:4-16 [PMID: 30826327]
  52. Eur J Pharmacol. 2020 Sep 15;883:173322 [PMID: 32619675]
  53. Rheumatol Int. 2018 Aug;38(8):1429-1435 [PMID: 29936571]
  54. Pain. 2013 Aug;154(8):1181-96 [PMID: 23707355]
  55. Biochim Biophys Acta. 2016 Apr;1862(4):576-591 [PMID: 26769361]
  56. Brain Res Bull. 2014 Aug;107:79-88 [PMID: 25038392]
  57. Mol Brain. 2020 Sep 5;13(1):121 [PMID: 32891169]
  58. Brain Res Bull. 2017 Sep;134:177-182 [PMID: 28739248]
  59. Neuropharmacology. 2012 Mar;62(4):1607-18 [PMID: 22019722]
  60. Br J Anaesth. 2019 Oct;123(4):506-518 [PMID: 31395306]
  61. Eur Arch Psychiatry Clin Neurosci. 2018 Jun;268(4):401-415 [PMID: 28526931]
  62. J Psychopharmacol. 2020 Jul;34(7):737-749 [PMID: 32312156]
  63. Pain Res Manag. 2017;2017:8296501 [PMID: 29302197]
  64. Brain Res. 2013 Nov 20;1539:73-86 [PMID: 24096214]
  65. Neuropharmacology. 2017 Apr;116:315-327 [PMID: 27567942]
  66. Depress Res Treat. 2012;2012:752563 [PMID: 23320155]
  67. Nitric Oxide. 2017 Nov 1;70:42-50 [PMID: 28821460]
  68. Semin Cancer Biol. 2018 Feb;48:62-69 [PMID: 28476657]
  69. Mol Pain. 2021 Jan-Dec;17:17448069211018045 [PMID: 34024172]

Grants

  1. PI1800645/Ministerio de Ciencia, Innovación y Universidades, Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea.

Word Cloud

Created with Highcharts 10.0.0painamygdalaeffectsbehaviorsgripstrengthslow-releasingHSdonorsosteoarthriticmemorychronicDADSGYY4137associatedcognitivedeficitscortexChronicosteoarthritisantidepressanthydrogensulfideimpairmentanxious-likedemonstratedmiceanxiodepressive-likeresponsesalsoand/orpropertiestreatmentsTreatmentoxidativestressperiaqueductalgraymatterinfralimbicaccompaniedseveralcomorbiditieswhosetreatmentcompletelyresolvedanti-inflammatoryanalgesicshownactionsaccompanyingyetUsingfemalenaturaldiallyldisulfidesyntheticmorpholin-4-ium4-methoxyphenylmorpholinophosphinodithioatedichloromethanecomplexassessedspecificbrainareasimplicatedmodulationemotionaldeterminedResultsimprovementwelltreatedpainkillerestablishedinhibited:phosphoinositide3-kinaseoverexpressionanteriorcingulateproteinkinaseBactivationup-regulationinduciblenitricoxidesynthaseapoptoticresultsmightexplainrecoveryinhibitionallodyniaconclusionstudyrevealednewaffectivedisorderslinkedcentralnervoussystemRecoveryCognitiveAffectiveDeficienciesLinkedOsteoarthritisPainImplicatedPathwaysSlow-ReleasingHydrogenSulfideanxietyapoptosisdepressionimpairments

Similar Articles

Cited By